MDMamoudou Harouna Djingarey

Mamoudou Harouna Djingarey

*This is an algorithmically generated author record based on publicly available information.

Mamoudou Harouna Djingarey has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A large epidemic of a necrotic skin infection in the Democratic Republic of São Tomé and Principe: an epidemiological study

    by Lorenzo Subissi, Andreza Sousa, Ibrahima Ba, Anne Perrocheau, Joshua Quick, Luke Meredith, Edmilson Augustinho, Beni Carvalho Sousa, Vania Lima, Jose Luiz, et al.


  • Open Access

    Limited specificity of serologic tests for SARS-CoV-2 antibody detection, Benin, Western Africa

    by Anges Yadouleton, Anna-Lena Sander, Andres Moreira-Soto, Carine Tchibozo, Gildas Hounkanrin, Yvette Badou, Carlo Fischer, Nina Krause, Petas Akogbeto, Edmilson F. de Oliveira Filho, et al.

    Testing 68 RT-PCR-confirmed COVID-19 cases and controls from Benin, Western Africa with commercially available SARS-CoV-2 antibody ELISAs revealed up to 25% false-positive results, likely due to unspecific antibody responses elicited by acute malaria. Serologic tests must be carefully evaluated to robustly assess SARS-CoV-2 spread and immunity in tropical regions.


  • Open Access

    Investigation of a cross-border case of Lassa fever in West Africa

    by Mory Keïta, Georges Alfred Kizerbo, Lorenzo Subissi, Fodé Amara Traoré, Ahmadou Doré, Mohamed Fode Camara, Ahmadou Barry, Raymond Pallawo, Mamadou Oury Baldé, Nfaly Magassouba, et al.

    Infectious disease prevention and control strategies require a coordinated, transnational approach. To establish core capacities of the International Health Regulations (IHR), the World Health Organization (WHO) developed the Integrated Diseases Surveillance and Response (IDSR) strategy. Epidemic-prone Lassa fever, caused by Lassa virus, is an endemic disease in the West African countries of Ghana, Guinea, Mali, Benin, Liberia, Sierra Leone, Togo and Nigeria. It’s one of the major public health threats in these countries. Here it is reported an epidemiological investigation of a cross-border case of Lassa fever, which demonstrated the importance of strengthened capacities of IHR and IDSR. On January 9th, 2018 a 35-year-old Guinean woman with fever, neck pain, body pain, and vomiting went to a hospital in Ganta, Liberia. Over the course of her illness, the case visited various health care facilities in both Liberia and Guinea. A sample collected on January 10th was tested positive for Lassa virus by RT-PCR in a Liberian laboratory. The Guinean Ministry of Health (MoH) was officially informed by WHO Country Office for Guinea and for Liberia. This case report revealed how an epidemic-prone disease such as Lassa fever can rapidly spread across land borders and how such threat can be quickly controlled with communication and collaboration within the IHR framework.


  • Open Access

    Lessons learned by surveillance during the tail-end of the Ebola outbreak in Guinea, June-October 2015: a case series

    by Mory Keïta, Fatoumata Conté, Boubacar Diallo, Dieudonné Lufwa, Jacques Katomba, René Snacken, Raymond Pallawo, Aminata Tolno, Amadou Bailo Diallo, Mamadou Harouna Djingarey, et al.

    By the end of the 2013–2016 West African Ebola Virus Disease (EVD) outbreaks, a total of 3814 cases (probable and confirmed) and 2544 deaths were reported in Guinea. Clearly, surveillance activities aiming at stopping human-to-human transmission have been the breakthrough of EVD outbreak management, but their application has been at times easier said than done. This article presents five confirmed or probable EVD cases that arose in Conakry towards the end of the Guinea epidemic, which demonstrate flaws in surveillance and follow-up. For case 1, safe burial requirements were not followed. For cases 1 and 2, negative Polymerase Chain Reaction (PCR) results were interpreted as no infection. For the first case, the sample may have not been taken properly while for the second the disease was possibly at its early stage. Case 3 was stopped at a border health checkpoint and despite her high temperature she was allowed to continue the bus journey. For case 4, an oral swab sample was supposedly taken after death but could not be found for retrospective testing. Despite characteristic symptomatology, case 5 was not identified as a suspect case for as long as 3 weeks. In epidemic contexts, health systems must be able to track all samples of suspect cases and deaths, regardless of their laboratory results. Social mobilization in communities and training in health care facilities must be strengthened at the tail of an outbreak, to avoid the natural slackening of disease surveillance, in particular for long-lasting and deadly epidemics.


  • Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso—Implications for introduction of PsA-TT into the Expanded Programme on Immunization

    by Sarah A. Meyer, Jean Ludovic Kambou, Amanda Cohn, James L. Goodson, Brendan Flannery, Isaïe Medah, Nancy Messonnier, Ryan Novak, Fabien Diomande, Mamoudou H. Djingarey, et al.